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healing at week 26; OR,Our post hoc analysis assessed the association of early (at weeks 26–30) clinical, endoscopic,
biologic, and pharmacokinetic outcomes with corticosteroid-free remission at week 50
(CSFR50); CSFR50 was observed in 55.2% and 65.4% of patients treated with inﬂiximab, alone
or in combination with azathioprine, respectively.METHODS: We analyzed data from 203 patients: 96 received inﬂiximab monotherapy and 107 received com-
bination therapy. Receiver operating characteristic analysis was used to set cut-off points for the
week30troughseruminﬂiximabconcentration(SIC30)andpercentagechange, frombaseline, in the
C-reactiveprotein (CRP) level atweek26, topredict CSFR50.Univariate andmultivariateprocedures
analyzed predictive parameters of CSFR50 (odds ratio [OR] and 95% conﬁdence interval [CI]).
Mucosal healing (MH, zero ulcers) and CRP normalization (<8.0 mg/L) also were assessed.RESULTS: Trough SIC30 was higher in patients with than without CSFR50. Patients given combination
therapy had higher trough SIC30s than those given monotherapy. Median trough SIC30 was
signiﬁcantly higher in patients with than without CSFR50 among those on inﬂiximab mono-
therapy (2.14 vs 0.80 mg/mL; P[ .006), but not for those on combination therapy (3.56 vs 3.54
mg/mL; P[.31). In patients with increased baseline levels of CRP (n[ 120), corticosteroid-free
remission at week 26 (CSFR26) (OR, 4.09; 95% CI, 1.65–10.11), and trough SIC30s of 3.0
mg/mL or greater (OR, 3.20; 95% CI, 1.38–7.42) were associated signiﬁcantly with CSFR50. In
patients evaluable for MH (n[ 123), trough SIC30s of 3.0 mg/mL or greater (OR, 3.34; 95% CI,
1.53–7.28) and CRP normalization (OR, 2.69; 95% CI, 1.10–6.54) were associated signiﬁcantly
with MH at week 26 (MH26). Furthermore, CSFR26 (OR, 4.43; 95% CI, 1.81–10.82) and MH26
(OR, 3.01; 95% CI, 1.33–6.81) were associated signiﬁcantly with CSFR50.CONCLUSIONS: Trough SIC30 is associated positively with MH26; CSFR26 and MH26 are independent pre-
dictors of CSFR50. Trough SIC30 of 3.0 mg/mL or greater early during maintenance treatment is
an important determinant of clinical and endoscopic Crohn’s disease outcomes. ClinicalTrials.
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Gastroenterology and Hepatology.Clinical challenges remain for predicting the long-term beneﬁt of biological treatment of patients
with Crohn’s disease (CD). Factors associated with better
long-term clinical and endoscopic outcomes in CD have
been studied.1,2 A therapeutic strategy of CD could
aim for clinical remission with mucosal healing (MH),
previously referred to as “deep remission.”3 Biological
remission deﬁned by a decrease or normalization of in-
ﬂammatory markers (ie, C-reactive protein [CRP] and/
or fecal biomarkers) may further enhance the deﬁnition
of deep remission into a “composite remission measure,”
including clinical, endoscopic, and biological remission.4
The association among serum inﬂiximab concentration
(SIC) and markers of clinical (eg, remission), endoscopic
(eg, MH), or inﬂammatory activity (eg, CRP) for better
long-term disease outcome is unknown.
Higher serum concentrations of biological drugs
including inﬂiximab,5 adalimumab,6 and certolizumab
pegol7 for the treatment of CD generally are associated
with better treatment outcomes, and exposure-response
relationships have been reported for all. Recently, a
trough SIC of 3.5 mg/mL or greater measured post-
induction at week 14 was found to be associated with a
sustained response to inﬂiximab 5 mg/kg induction and
maintenance therapy in A Crohn’s Disease Clinical Trial
Evaluating Inﬂiximab in a New Long-term Treatment
Regimen I (clinicaltrials.gov NCT00207662).5 A recent
post hoc analysis of the Endoscopic Mucosal Improve-
ment in Patients With Active CD Treated With Certoli-
zumab trial (clinicaltrials.gov NCT00297648) in patients
with active CD and severe endoscopic disease showed
that endoscopic response and remission at week 10
(deﬁned as a Crohn’s disease endoscopic index score
[CDEIS] decrease from baseline >5 and CDEIS <6,
respectively) was associated with higher plasma con-
centrations of certolizumab pegol measured at week
8 (4 weeks after the last loading dose of 400 mg).7
Still, clinicians mainly evaluate the effect of CD ther-
apies on the basis of their patients’ signs and symptoms.
In the Study of Biologic and Immunomodulator Naive
Patients in Crohn’s Disease (SONIC) (clinicaltrial.gov
NCT00094458), patients naive to both immunomodula-
tors and biologics with moderate-to-severe CD activity
were randomized to azathioprine monotherapy or 1 of 2
inﬂiximab-based treatment regimens.8 The primary end
point was corticosteroid-free remission at week 26
(CSFR26), and secondary end points included
corticosteroid-free remission at week 50 (CSFR50) and
mucosal healing at week 26 (MH26).
The primary endpoint of SONIC (CSFR26) was ach-
ieved in 30.0%, 44.4%, and 56.8% of patients treated
with azathioprine monotherapy, inﬂiximab monotherapy,
or azathioprine plus inﬂiximab combination therapy,respectively.8 The biological treatment effect was greater
in patients with baseline ulcers and in patients with
increased baseline CRP levels, both of which are
considered objective markers of inﬂammation in CD.
Furthermore, median trough SICs at week 30 (SIC30)
were 1.6 and 3.5 mg/mL in the inﬂiximab monotherapy
and azathioprine plus inﬂiximab combination therapy
groups, respectively (P < .001).8
In this post hoc analysis of SONIC, we investigated
factors associated with CSFR50 and MH26 including
CSFR26, change (decrease) in CRP level from baseline at
week 26 (DCRP26), CRP normalization at week 26, and
trough SIC30 for inﬂiximab-treated patients by treat-
ment group (ie, inﬂiximab monotherapy and inﬂiximab
and azathioprine combination therapy).
Methods
In SONIC, patients were assigned randomly to receive
intravenous infusions of 5 mg/kg inﬂiximab (Remicade;
Janssen Biotech, Inc, Horsham, PA) plus daily oral pla-
cebo capsules, oral azathioprine capsules at a daily dose
of 2.5 mg/kg plus placebo infusions, or combination
therapy with inﬂiximab and azathioprine.8 Infusions
were administered at weeks 0, 2, and 6, and then every 8
weeks. Patients were followed up through week 30,
when they were given the option of continuing to receive
their blinded therapy in a 20-week extension trial, with
follow-up evaluation through week 50.
In this post hoc analysis, we included 203 patients
who received inﬂiximab plus placebo (hereafter referred
to as inﬂiximab monotherapy; n ¼ 96) or inﬂiximab plus
azathioprine treatment (hereafter referred to as inﬂix-
imab combination therapy; n ¼ 107) who had baseline
and week 26 CRP measurements, and trough SIC30
measurements to evaluate their association with CSFR50
(Table 1). Among these 203 patients, 13 patients in each
treatment group did not enter the extension and were
treated as not achieving CSFR50.
In the subgroup of 203 patients with increased
(8.0 mg/L) baseline CRP level (n ¼ 120), we investi-
gated the association between DCRP26, CRP normaliza-
tion at week 26 (CRP < 8.0 mg/L), and CSFR50.
Furthermore, among the subset of 203 patients
who had evaluable endoscopies at baseline and week 26
(n ¼ 123) (Table 1), we assessed the association of
CSFR50 with MH26 (deﬁned as 0 ulcers and/or ero-
sions), and the association of MH26 and SIC30.
Our data set (N ¼ 203) was smaller than the original
SONIC data set, which included 169 patients who
received inﬂiximab combination therapy and 169 pa-
tients who received inﬂiximab monotherapy, because
only those patients who had baseline and week 26 CRP
measurements and trough SIC30 measurements
were eligible to be included in this post hoc study to
evaluate the relationship between these parameters
and CSFR50.
Table 1. Patient Characteristics
Inﬂiximab
monotherapy
Inﬂiximab
combination therapy
All inﬂiximab-treated
patients
All patients randomized to inﬂiximab-based
therapy in SONIC, N
169 169 338
Post hoc analysis populations
Patients with complete week 26 and
week 30 data, N
96 107 203
Age, mean (SD), y 37.7 (13.96) 36.4 (11.49) 37.0 (12.70)
Sex, male/female 45/51 59/48 104/99
Patients in extension, n (%) 83 (86.5) 94 (87.9) 177 (87.2)
CSFR26, n (%) 64 (66.7) 77 (72.0) 141 (69.5)
CSFR50, n (%) 53 (55.2) 70 (65.4) 123 (60.6)
Patients with increased CRP level, N 58 62 120
Age, mean (SD), y 35.1 (12.63) 34.1 (11.24) 34.6 (11.89)
Sex, male/female 27/31 32/30 59/61
Patients in extension, n (%) 50 (86.2) 57 (91.9) 107 (89.2)
CSFR26, n (%) 41 (70.7) 49 (79.0) 90 (75.0)
CSFR50, n (%) 31 (53.5) 43 (69.4) 74 (61.7)
Patients with all mucosal healing data, N 56 67 123
Age, mean (SD), y 36.8 (14.54) 36.5 (11.19) 36.6 (12.77)
Sex, male/female 26/30 33/34 59/64
Patients in extension, n (%) 48 (85.7) 59 (88.1) 107 (87.0)
CSFR26, n (%) 42 (75.0) 50 (74.6) 92 (74.8)
CSFR50, n (%) 36 (64.3) 45 (67.2) 81 (65.9)
MH26, n (%) 26 (46.4) 44 (65.7) 70 (56.9)
NOTE. Patients with increased CRP level (8.0 mg/L) and patients with mucosal healing data are subgroups of patients with all week 26 and week 30 data.
Patients who did not enter study extension were assumed to have not achieved CSFR at week 50 as used for the SONIC main analysis.
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immunoassay (Charles River Laboratories, Inc [formerly
Tektagen, Inc], Wilmington, MA).9 Note that unlike the
ongoing Study Investigating Tailored Treatment with
Inﬂiximab for Active Crohn’s Disease (clinicaltrials.gov
NCT01442025), the SONIC trial design did not include
dose ﬂexibility and cannot be considered a treat-to-
target study.
Statistical analyses were performed using SAS 9.1
and 9.2 (SAS Institute, Inc, Cary, NC). Receiver operating
characteristic (ROC) curves were constructed for the
sensitivity and speciﬁcity analyses of SIC30 (mg/mL)
and DCRP26 to predict CSFR50 and MH26. Selection of
a useful cut-off value for SIC30 and DCRP26 (percentage
change) to discriminate patients with and without
CSFR50 were determined by sensitivity/speciﬁcity
tables.
Median (interquartile range [IQR]) SIC30 measure-
ments were compared between patients with or without
CSFR50 with the use of the Wilcoxon rank sum test.
The chi-square test was used to compare proportions
of patients achieving CSFR50 between those who did or
did not reach the optimal SIC30 cut-off value.
Univariate logistic regression and multivariate logistic
regression models with stepwise selection, including the
dichotomous (yes/no) parameters CSFR26, SIC30s of 3.0
mg/mL or greater, DCRP26 of 45% or greater, CRP
normalization (<8.0 mg/L) from baseline at week 26,
presence of MH26, and treatment group (inﬂiximab
monotherapy vs inﬂiximab combination therapy) wereused to select best-ﬁt parameters that were associated
signiﬁcantly with CSFR50 and MH26.
Study procedures were performed in accordance with
all institutional review boards and with the Helsinki
Declaration. All patients provided written informed
consent. All authors had access to the study data and
reviewed and approved the ﬁnal manuscript.Results
Associations With Corticosteroid-Free
Remission at Week 50: Univariate and
Multivariate Analyses
A positive association was observed between CSFR26
and CSFR50 (N ¼ 203; P < .001). Overall, 101 (49.8%)
patients who achieved CSFR26 also achieved CSFR50 vs
22 (10.8%) who did not achieve CSFR26 but achieved
CSFR50 (data not shown). The odds ratio (OR) of
achieving CSFR50 for patients in CSFR26 was 4.59 times
that of those who did not achieve CSFR26 (95% conﬁ-
dence interval [CI], 2.43–8.67; P < .001). Multivariate
analysis with stepwise selection procedure provided
similar results (Tables 2 and 3).
The ROC curve using SIC30s for all inﬂiximab-treated
patients (N ¼ 203) identiﬁed a cut-off value of 3.0 mg/mL
(area under the curve [AUC], 0.628; sensitivity, 0.50;
speciﬁcity, 0.65) (Figure 1A), which was associated signif-
icantlywith CSFR50. Among all inﬂiximab-treated patients,
Table 2. Logistic Regression Analysis of Possible Predictive Factors of CSFR50 and Mucosal Healing in SONIC
Analysis subgroup
Univariate analysis Stepwisea logistic regression
OR 95% CI P value OR 95% CI P value
CSFR50 (N ¼ 203)
Study group (inﬂiximab combination
therapy/inﬂiximab monotherapy)
1.53 (0.87–2.70) .138
CSFR26, yes/no 4.59 (2.43–8.67) <.001 4.51 (2.37–8.58) <.001
Trough SIC30  3 mg/mL, yes/no 1.89 (1.06–3.37) .032 1.82 (0.98–3.36) .057
CSFR50 (N ¼ 120) (patients with baseline
CRP level  8.0 mg/L)
Study group (inﬂiximab combination
therapy/inﬂiximab monotherapy)
1.97 (0.93–4.16) .075
CSFR26, yes/no 4.03 (1.69–9.61) .002 4.09 (1.65–10.11) .002
CRP normalization, yes/no 2.89 (1.33–6.30) .007
DCRP26  45%, yes/no 3.16 (1.24–8.07) .016
Trough SIC30  3 mg/mL, yes/no 3.16 (1.42–7.03) .005 3.20 (1.38–7.42) .007
CSFR50 (N ¼ 123) (patients with all mucosal
healing data)
MH26, yes/no 3.25 (1.50–7.06) .003 3.01 (1.33–6.81) .008
Study group (inﬂiximab combination
therapy/inﬂiximab monotherapy)
1.14 (0.54–2.40) .737
CSFR26, yes/no 4.75 (2.00–11.26) <.001 4.43 (1.81–10.82) .001
CRP normalization, yes/no 1.40 (0.60–3.28) .438
Trough SIC30  3 mg/mL, yes/no 1.84 (0.86–3.97) .118
MH26 (N ¼ 123)
Study group (inﬂiximab combination
therapy/inﬂiximab monotherapy)
2.21 (1.07–4.57) .033
DCRP26  45%, yes/no 1.89 (0.83–4.30) .129
CRP normalization, yes/no 3.00 (1.28–7.04) .012 2.69 (1.10–6.54) .029
Trough SIC30  3 mg/mL, yes/no 3.58 (1.67–7.69) .001 3.34 (1.53–7.28) .002
aA stepwise procedure was used when variables were added if P < .1, and were removed if P  .11.
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associated signiﬁcantly with CSFR50 (OR, 1.89; 95% CI,
1.06–3.37; P¼ .032) (Tables 2 and 3).Multivariate analysis
with stepwise selection procedure suggested a meaningful
trend of association between these 2 parameters (OR, 1.82;
95% CI, 0.98–3.36; P ¼ .057) (Table 2).
In patients with increased baseline CRP level (CRP
level  8.0 mg/L; n ¼ 120), CRP change from baseline
and CRP normalization at week 26 were associated with
CSFR50 (Table 2). The ROC curve using the percentage
DCRP26 for all patients with increased baseline CRP
level identiﬁed a cut-off value of 45% or greater DCRP26
for differentiating patients with and without CSFR50
(AUC, 0.611; sensitivity, 0.88; speciﬁcity, 0.30)
(Figure 1B). Among all patients with increased baseline
CRP level, 65 of 97 (67.0%) patients with 45% or greater
CRP decrease were in CSFR50 compared with 9 of 23
(39.1%) patients with less than a 45% CRP decrease
(P ¼ .013) (Supplementary Table 1). The likelihood of
being in CSFR50 among patients with a 45% or greater
DCRP26 was signiﬁcantly greater compared with those
with less than 45% DCRP26 (OR, 3.16; 95% CI,
1.24–8.07; P ¼ .016). Similarly, the likelihood of being in
CSFR50 among patients with normalized CRP level (<0.8
mg/dL) at week 26 was signiﬁcantly greater than those
with increased CRP level (OR, 2.89; 95% CI, 1.33–6.30;
P ¼ .007) (Table 2). In this subgroup of patients withincreased baseline CRP level, CSFR26 and SIC30 mea-
surement of 3.0 mg/mL or greater also were associated
with CSFR50 (OR, 4.03; 95% CI, 1.69–9.61 and OR, 3.16;
95% CI, 1.42–7.03, respectively; Tables 2 and 3). In this
subgroup of patients with increased baseline CRP level,
CSFR26 and SIC30 measurement of 3.0 mg/mL or greater
seems to have a stronger association with CSFR50 (OR,
4.03; 95% CI, 1.69–9.61 and OR, 3.16; 95% CI, 1.42–7.03,
respectively; Tables 2 and 3) than CRP normalization
because when all parameters were included in the
multivariate logistic regression model, CSFR26 and
trough SIC30 measurement of 3.0 mg/mL or greater
remained signiﬁcantly associated with CSFR50.
Among patients eligible for MH analysis (n ¼ 123),
both univariate and multivariate logistic regression
analyses showed that MH26 was associated signiﬁcantly
with CSFR50 (OR, 3.25; 95% CI, 1.50–7.06; P ¼ .003),
and CSFR26 remained signiﬁcantly associated with
CSFR50 (OR, 4.75; 95% CI, 2.00–11.26; P < .001)
(Table 2 and Supplementary Table 2).
Associations With Mucosal Healing at Week 26
The ROC curve using SIC30 measurements also
identiﬁed a cut-off value of 3.0 mg/mL (AUC, 0.638;
sensitivity, 0.59; speciﬁcity, 0.72) (Figure 2) that was
associated signiﬁcantly with MH26 (n ¼ 123).
Table 3. Association Between CSFR50 and Trough SIC30
Trough SIC30 Patients with CSFR50 Patients without CSFR50 All patients P valuea
All inﬂiximab-treated patients, N 123 80 203
Median (IQR), mg/mL 3.1 (1.2–6.0) 1.7 (0.1–3.7) .002
Inﬂiximab combination therapy, N 70 37 107
Median (IQR), mg/mL 3.56 (1.74–8.64) 3.54 (1.43–5.02) .31
Inﬂiximab monotherapy, N 53 43 96
Median (IQR), mg/mL 2.14 (0.48–4.54) 0.80 (0.0–2.15) .006
P valueb .005 <.001
3.0 mg/mL SIC30, n (%) 62 (68.9) 28 (31.1)
<3.0 mg/mL SIC30, n (%) 61 (54.0) 52 (46.0) .03
aP value from the Wilcoxon rank sum test for serum inﬂiximab concentrations and chi-square test for serum inﬂiximab categories, comparing patients with CSFR50
and without CSFR50.
bP values from the Wilcoxon rank sum test comparing median SIC30 between the inﬂiximab combination therapy and inﬂiximab monotherapy groups.
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3.0 mg/mL or greater (n ¼ 56), 41 (73.2%) had MH26
and 15 (26.8%) did not. Conversely, among patients with
SIC30 measurements of less than 3.0 mg/mL (n ¼ 67), 29
(43.3%) had MH26 and 38 (56.7%) did not (P < .001)
(Supplementary Table 3).
In univariate analysis, study group (inﬂiximab com-
bination vs inﬂiximab monotherapy), CRP normalization
at week 26, and SIC30 measurements of 3.0 mg/mL or
greater were associated signiﬁcantly with MH26,
whereas CSFR26 was not (Table 2). In multivariate
analysis, CRP normalization and SIC30 measurements of
3.0 mg/mL or greater were associated signiﬁcantly with
MH26 (OR, 2.69; 95% CI, 1.10–6.54; P ¼ .029 and OR,
3.34; 95% CI, 1.53–7.28; P ¼ .002, respectively) (Table 2
and Supplementary Table 2).Trough Serum Inﬂiximab Concentration at
Week 30 in Patients Receiving Inﬂiximab
Combination Therapy Versus Inﬂiximab
Monotherapy
The median SIC30 measurement was 2.4 mg/mL (IQR,
0.8–5.0 mg/mL) among all inﬂiximab patients (N ¼ 203).
The median SIC30 measurement was signiﬁcantly
higher in patients who achieved CSFR50 (OR, 3.1; 95% CI,
1.2–6.0 mg/mL; n ¼ 123) than for those who did not (OR,
1.7; 95% CI, 0.1–3.7 mg/mL; n ¼ 80; P ¼ .002) (Table 3).
Among all patients, 68.9% (62 of 90) with SIC30 mea-
surements of 3.0 mg/mL or greater achieved CSFR50,
compared with 54.0% (61 of 113) with SIC30 measure-
ments of less than 3.0mg/mLwho achieved CSFR50,which
was a 14.9% difference (P ¼ .03) (Table 3).
Treatment group (inﬂiximab monotherapy vs inﬂix-
imab combination therapy) affected the SIC30. In pa-
tients with CSFR50, SIC30 was signiﬁcantly higher with
inﬂiximab combination therapy (median, 3.56 mg/mL;
IQR, 1.74–8.64 mg/mL vs median, 2.14 mg/mL; IQR,
0.48–4.54 mg/mL, respectively; P ¼ .005) (Table 3). In
patients without CSFR50, the median SIC30 also was
higher with combination therapy (3.54 and 0.80 mg/mL,
respectively; P < .001) (Table 3).Among patients who received inﬂiximab mono-
therapy, the median SIC30 measurement was signiﬁ-
cantly higher for patients who achieved CSFR50 than for
those who did not (2.14 and 0.80 mg/mL, respectively;
P ¼ .006). This was not observed among patients who
received inﬂiximab combination therapy (3.56 and
3.54 mg/mL, respectively; P ¼ .31) (Table 3).
The CSFR50 is shown for SIC30 ranges, ranges that
were reported previously,9 and includes patients with
undetectable SIC30 measurements (Figure 3). Higher
SIC30 measurements were associated with higher
CSFR50 rates among all inﬂiximab-treated patients
(N ¼ 203; P ¼ .014), patients treated with monotherapy
(n ¼ 96; P ¼ .010), but not patients treated with com-
bination therapy (n ¼ 107; P ¼ .25). Only 3 of 107
(2.8%) patients treated with inﬂiximab combination
therapy compared with 29 of 96 (30.2%) patients
treated with inﬂiximab monotherapy had no measurable
SIC30 (Figure 3).
In the inﬂiximab monotherapy group (n ¼ 96), 23 of
31 (74%) patients with SIC30 measurements greater
than 3.0 mg/mL were in CSFR50 compared with 30 of 65
(46%) patients in CSFR50 with SIC30 measurements of
less than 3.0 mg/mL (Figure 3). In contrast, 60% or more
of patients in any inﬂiximab concentration range greater
than 0.1 mg/mL achieved CSFR50 in the inﬂiximab
combination therapy group (Figure 3).
As previously reported, among patients treated with
inﬂiximab who had week 30 pharmacokinetic samples
for antibody to inﬂiximab (ATI) analysis (N ¼ 219), 16
were positive, 18 were negative, and 185 were incon-
clusive.8 CSFR26 was achieved in 56% (9 of 16), 67%
(12 of 18), and 72% (133 of 185) of patients with a week
30 ATI status of positive, negative, and inconclusive
(because of SIC30 0.1 mg/mL or greater), respectively.Discussion
This post hoc analysis of SONIC conﬁrms the impor-
tance of measurable SICs for good clinical and endo-
scopic outcomes in patients with CD. In SONIC, patients
in CSFR50 have higher median SIC30 measurements
Figure 1. ROC curve for detecting CSFR50 using (A) SIC30 for all inﬂiximab-treated patients combined (N ¼ 203); CSFR50
(n ¼ 123), no CSFR50 (n ¼ 80) or (B) using percent reduction from baseline in CRP at week 26 (n ¼ 120); CSFR50 (n ¼ 46), no
CSFR50 (n ¼ 74). ROC, receiver operating characteristic; CSFR50, corticosteroid-free remission at week 50; SIC30, serum
inﬂiximab concentration at week 30; CRP, C-reactive protein; AUC, area under the curve.
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respectively; P ¼ .002). We identiﬁed SIC30 measure-
ments of 3.0 mg/mL or greater as a useful cut-off value to
differentiate patients with and without CSFR50. CSFR50
and MH26 were signiﬁcantly associated with SIC30
measurements of 3.0 mcg/mL or greater. In univariate
and multivariate analyses, the SIC30 measurements of
3.0 mg/mL or greater was the most signiﬁcant determi-
nant of MH26. In the Endoscopic Mucosal Improvement
in Patients With Active CD Treated With Certolizumab
trial, week 8 certolizumab pegol plasma concentrations
also were associated signiﬁcantly with CDEIS remission
(score, <6) at week 10.7 In SONIC, MH was deﬁned as
0 ulcers. We thus speculate that SIC30 measurements of
3 mg/mL or greater result in adequate neutralization of
tumor necrosis factor in the bowel mucosa with ulcer
healing. In the large Leuven CD cohort, more patients
receiving scheduled maintenance treatment had com-
plete MH (52.0%) compared with patients treated
episodically (37%; P ¼ .052). In addition, patients
initially receiving scheduled maintenance treatment had
signiﬁcantly higher MH rates (60 of 78; 76.9%)
compared with those who received episodic treatment
throughout follow-up evaluation (23 of 40; 57.5%; P ¼
.035).10 This further suggests that adequate SICs need to
be sustained to maintain mucosal improvement and ul-
cer healing.
A recent study by Bortlik et al11 used a 3.0 mg/mL
trough SIC at week 14 or week 22 to predict long-term
therapeutic beneﬁt deﬁned as sustained clinical
response without the need for new introduction of im-
munomodulators, corticosteroids, or any dose increase.
Inﬂiximab dose increase, however, was allowed to sus-
tain response. In this study,11 the median week 14 to22 trough SIC was 4.04 mg/mL (IQR, 0.52–9.33 mg/mL).
In multivariate analysis, only week 14 to 22 trough SIC
was a signiﬁcant predictor of sustained response (loss of
response: OR, 0.31; 95% CI, 0.10–0.96). The study by
Bortlik et al11 did not include mucosal healing outcome
as a possible predictor of long-term beneﬁt of inﬂiximab
therapy. These results, based on a daily practice CD
cohort, thus largely are in agreement with our SONIC
post hoc analysis, and previous analysis of clinical out-
comes associated with week 14 SIC measurements in A
Crohn’s Disease Clinical Trial Evaluating Inﬂiximab in a
New Long-term Treatment Regimen I.5
In SONIC, the median SIC30 measurements were 1.6
mg/mL and 3.5 mg/mL for the inﬂiximab monotherapy
(n ¼ 97) and inﬂiximab combination therapy groups
(n ¼ 109), respectively, and the proportion of inﬂiximab-
treated patients in CSFR26 in previously summarized
concentration ranges of 0.0, greater than 0.0 to 1.0,
greater than 1.0 to 3.0, greater than 3.0 to 6.0, and
greater than 6.0 mg/mL SIC30 showed 72% to 73%
CSFR26 with more than 3.0 mg/mL from the 2 highest
concentration quintiles compared with 57% to 59%
CSFR26 for patients with less than 3.0 mg/mL concen-
tration among the 3 lowest quintiles.8 Although SONIC
was not designed to study dose ﬂexibility, we observed
that 3.0 mg/mL or greater was associated signiﬁcantly
with better clinical outcomes in patients with CD treated
with inﬂiximab combination therapy. A cut-off value of
3.0 mg/mL was identiﬁed for the combined inﬂiximab
monotherapy/combination therapy treatment groups;
however, analysis of these groups separately identiﬁed a
higher cut-off value for inﬂiximab monotherapy (4.0
mg/mL; data not shown). Combination therapy resulted
in higher trough SIC measurements, and inﬂiximab
Figure 3. Association of CSFR50 using selected SIC30
ranges. Note: Patients with inﬂiximab concentrations less
than .1 mg/mL, are classiﬁed as zero. SIC30, serum inﬂiximab
concentration at week 30; CSFR50, corticosteroid-free
remission at week 50.
Figure 2. ROC curve for detecting MH26 using SIC30 in pa-
tients with all mucosal healing data (n ¼ 123); with mucosal
healing (n ¼ 70), no mucosal healing (n ¼ 53). ROC, receiver
operating characteristic; MH26, mucosal healing at week 26;
SIC30, inﬂiximab serum concentration at week 30; AUC, area
under the curve.
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same SIC and successful clinical outcome.
In SONIC, inﬂiximab concentration and ATI data were
only collected at weeks 30 and 46. It is possible that
positive ATI samples (and undetectable SIC) occurred in
patients who discontinued the study early. In the study
by Bortlik et al,11 however, low SIC measurements (less
than 3.0 mg/mL) but not ATI measurements were as-
sociated signiﬁcantly with early (weeks 14 to 22) loss
of response to inﬂiximab in patients with CD.
Among patients with increased baseline CRP levels, a
45% DCRP26 was associated signiﬁcantly with CSFR50,
and all but 1 patient with 45% or greater DCRP26 (77 of
78) also had normalized CRP levels (less than 8.0 mg/L).
C-reactive protein normalization is an established
marker of good clinical outcome in the treatment of CD
with inﬂiximab.12,13 Our results, therefore, are in agree-
ment with those of Feagan et al,14 who analyzed 532
patients with CD who participated in 4 prospective
randomized controlled trials, or cohort studies. For the
present analyses, data from 2021 serum samples were
combined and the correlation between inﬂiximab and
CRP concentrations was evaluated. A SIC30 measure-
ment greater than 3 mg/mL as shown by ROC curve
analysis predicted signiﬁcantly lower disease activity, as
measured by CRP level.
By univariate analysis, SIC30 measurements of
3.0 mg/mL, CRP normalization at week 26, and treatment
group were associated signiﬁcantly with MH26, whereas
MH26 and CSFR26 were associated signiﬁcantly with
CSFR50. By multivariate analysis, both CSFR26 and MH26
remained signiﬁcantly associated with CSFR50. It thus is
important to achieve MH for long-term beneﬁt. Both CRP
normalization at week 26 (OR, 2.69; 95% CI, 1.10–6.54;P ¼ .029) and SIC30 measurement of 3.0 mg/mL or
greater (OR, 3.34; 95% CI, 1.53–7.28; P ¼ .002) were
associated signiﬁcantly with MH26. Interestingly, CSFR26
and MH26 (P ¼ .129) were not associated. This suggests
that CD signs and symptoms as measured by the Crohn’s
Disease Activity Index are not objective markers of
inﬂammation, in contrast to endoscopic (eg, mucosal ul-
cerations) and biological (eg, increased CRP level) out-
comes. The disconnection between CD clinical symptoms
and endoscopic and biological markers of inﬂammation
was documented clearly in a previous SONIC post hoc
analysis.15
Our study had limitations. First, this was a post hoc
study of SONIC data from the 2 study groups treated
with inﬂiximab (ie, excluding the azathioprine mono-
therapy group), and the reported analyses were not
prespeciﬁed. The primary end point of SONIC was
CSFR26. Nevertheless, these analyses add clinically use-
ful insight to the importance of CSFR26 and MH26 for
attaining long-term beneﬁt of inﬂiximab treatment such
as CSFR50 in patients with CD. Second, the patient
population that entered the extension of the SONIC trial
after the primary end point at week 26 may have been
biased toward responders at week 26 because continu-
ation was at the discretion of the patient and investi-
gator. Third, our results were generated from a selected
cohort of SONIC patients for whom the clinical and
pharmacokinetic proﬁles may not be generalizable to
patients in daily inﬂammatory bowel disease practices.
Therapeutic drug monitoring is an area of great
clinical interest because it may allow much better
personalized use of biological drugs by deﬁning a ther-
apeutic window for a given patient with target
concentration-adjusted dosing to prevent loss of
546 Reinisch et al Clinical Gastroenterology and Hepatology Vol. 13, No. 3response, and to reduce possible safety risks associated
with supratherapeutic drug concentrations.16 Prospec-
tive trials are needed to evaluate the clinical value of
therapeutic drug monitoring and target concentration-
adjusted inﬂiximab dosing. Results of prospective
studies such as the recently reported A Prospective
Controlled Trough Level Adapted Inﬂiximab Treatment
trial17 and the ongoing Study Investigating Tailored
Treatment with Inﬂiximab for Active Crohn’s Disease
may help optimize treatment algorithms.
In summary, this post hoc analysis of SONIC shows
that MH26 is associated signiﬁcantly with SIC30
measurements of 3.0 mg/mL or greater and CRP
normalization at week 26, and that MH26 and CSFR26
are associated signiﬁcantly with CSFR50. Therefore,
the short-term goals of CD treatment may include
pharmacokinetic proﬁling, and biologic (CRP) and
endoscopic (MH) remission.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2014.09.031.References
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Supplementary Table 1. Association Between CRP and CSFR50
Patients with
CSFR50
Patients
without CSFR50 Total patients P valuea
All inﬂiximab-treated patients, N 123 80 203
Increased baseline CRP level 8.0 mg/L, n 74 46 120
CRP decrease  45% from baseline at
week 26, n (%)
65 (67.0) 32 (33.0) 97
CRP decrease < 45% from baseline at
week 26, n (%)
9 (39.1) 14 (60.9) 23 .013
NOTE. Patients with increased CRP level at baseline: N ¼ 120.
aP value from the chi-square test comparing the percentage of patients with those without CSFR50 by CRP decrease from baseline (45% or <45%) categories.
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Signiﬁcantly associated factors Sensitivity
CSFR50
Week 26 CSFR, yes/no 0.821
Week 26 CRP level < 0.8 mg/dL, yes/no 0.813
SIC30 3 mg/mL, yes/no 0.504
Week 26 CRP level < 0.8 mg/dL, yes/noc 0.743
Week 26 mucosal healing, yes/nod 0.667
MH26
Week 26 CRP < 0.8 mg/dL, yes/no 0.843
SIC30  3 mg/mL, yes/no 0.586
NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likeli
aPLR ¼ sensitivity/(1 - speciﬁcity) ¼ factor by which the odds for true positive in
bNLR ¼ (1 - sensitivity)/speciﬁcity ¼ factor by which the odds for true positive de
cAmong patients with baseline CRP level > 0.8 mg/dL.
dAmong patients eligible for mucosal healing evaluation.Factors Signiﬁcantly Associated With CSFR50 or MH26
Speciﬁcity PPV NPV PLRa NLRb
0.500 0.716 0.645 1.64 0.36
0.313 0.645 0.521 1.18 0.60
0.650 0.689 0.460 1.44 0.76
0.500 0.705 0.548 1.49 0.51
0.619 0.771 0.491 1.75 0.54
0.358 0.634 0.633 1.31 0.44
0.717 0.732 0.567 2.07 0.58
hood ratio; PPV, positive predictive value.
crease given that a patient tests positive.
crease given that a patient tests negative.
Supplementary Table 3. Association of MH26, CSFR50, and
SIC30 (N ¼ 123)
MH26
P valuea
Mucosal
healing
No mucosal
healing
SIC30
3 mg/mL 41 (73.2%) 15 (26.8%)
<3 mg/mL 29 (43.3%) 38 (56.7%) <.001
CSFR50
MH26 CSFR50 No CSFR50
Yes 54 (77.1%) 16 (22.9%)
No 27 (50.9%) 26 (49.1%) .002
aP value from the chi-square test comparing percentages of patients with
CSFR50 with those without CSFR50 by SIC and mucosal healing status.
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